NSE · ADVENZYMES · Pharmaceuticals
Advanced Enzyme Technologies Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹781 Cr with net profit ₹169 Cr — a 21.61% net margin, versus 19.16% the period before.
Shareholding
As of 2026-06-30
- Promoter43.24%
- Public25.27%
- FII26.71%
- DII4.78%
63,599 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.66× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #39 of 102 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,77,444 Cr | 38.42 | 5.71 | 13.74% | 19.72% |
| Cipla Ltd. | ₹1,19,101 Cr | 214.6 | 3.46 | 11.27% | 14% |
| Zydus Lifesciences Ltd. | ₹1,11,990 Cr | 20.62 | 4.13 | 18.59% | 18.86% |
| Lupin Limited | ₹1,11,885 Cr | 70.26 | 4.98 | 23.76% | 19.4% |
| Mankind Pharma Limited | ₹1,07,077 Cr | 192.91 | 6.57 | 11.74% | 13.4% |
| Laurus Labs Limited | ₹96,235 Cr | 344.55 | 18.14 | 16.77% | 13.05% |
| Dr Reddys Laboratories Ltd. | ₹95,344 Cr | 431.06 | 2.52 | 0.11% | 0.12% |
| Aurobindo Pharma Ltd. | ₹92,388 Cr | 100.3 | 2.44 | 9.25% | 10.5% |
| Biocon Ltd. | ₹69,942 Cr | 546.2 | 2.06 | 1.14% | 2.3% |
| Alkem Laboratories Ltd. | ₹67,823 Cr | 286.92 | 4.91 | 16.66% | 15.65% |
| Advanced Enzyme Technologies Ltd.(this company) | ₹3,480 Cr | 80.94 | 2.13 | 10.34% | 22.62% |
AI analysis
AI-generated · google/gemini-2.5-flashAdvanced Enzyme Technologies Ltd. is listed on the Indian markets with a market capitalization of Rs 3573 Cr. The company reported revenue of Rs 669.95 Cr and a Net Profit of Rs 168.719 Cr for the financial year ending March 2026. Its earnings per share (EPS) for the same period stood at Rs 9.15. The debt-to-equity ratio is 0.00.
Positives
- +The company has a low debt-to-equity ratio of 0.00, indicating no debt.
- +Promoter holding of 43.2409% suggests a significant stake held by the promoters.
- +The company has no promoter share pledging recorded.
Negatives
- −Revenue decreased from Rs 780.589 Cr in March 2026 to Rs 669.95 Cr in the current reporting period by 14.20%.
- −Net profit decreased from Rs 168.719 Cr in March 2026 to Rs 100.91 Cr (calculated as 669.95 - (81.45+29.67+21.72+28.9)) in the current reporting period by 40.17%.
Financial Performance
For the financial year ending March 2026, Advanced Enzyme Technologies Ltd. recorded a revenue of Rs 780.589 Cr. The net profit for the same period was Rs 168.719 Cr, resulting in an earnings per share (EPS) of Rs 15.06. Quarterly performance shows a revenue of Rs 203.37 Cr and net profit of Rs 42.96 Cr for the quarter ending March 2026.
Profitability & Returns
The company's return on equity (ROE) is 16.9% and return on capital employed (ROCE) is 14.13%. The earnings per share (EPS) for the latest available annual data is Rs 9.15. The company reported an EBITDA of Rs 223.805 Cr for the financial year ending March 2026.
Balance Sheet
Advanced Enzyme Technologies Ltd. has a book value of Rs 56.25. The debt-to-equity ratio is 0.00, indicating no debt. This financial structure suggests a reliance on equity for funding operations.
Ownership & Pledges
As of June 30, 2026, the promoter holding in the company is 43.2409%. The public shareholding stands at 25.27%. There is no promoter share pledging recorded.
Data as of — price: 2026-07-29 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Advanced Enzyme Technologies Ltd.share price & fundamentals